You are here: Industry Insights > AZ

News List

Speedy review for AZ’ Lynparza in breast cancer pharmatimes
October 20, 2017
AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.
AZ’ lung cancer drug Tagrisso bags breakthrough status pharmatimes
October 11, 2017
AstraZeneca’s Tagrisso has been awarded breakthrough status in the US as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC), potentially speeding up its development and regulatory pathway.
AZ and MSD secure three bits of good news on key drug pharmafile
August 21, 2017
It was a case of three-in-one bits of good news for AstraZeneca and MSD, after the FDA boosted the newly formed Lynparza partnership with an expanded indication and new formulation approval.
Priority review and breakthrough status for AZ’ acalabrutinib pharmatimes
August 03, 2017
straZeneca and group member Acerta Pharma say acalabrutinib is being given a priority review by the US Food and Drug Administration for mantle cell lymphoma (MCL)...
Breakthrough status for AZ’ lung cancer drug Imfinzi pharmatimes
August 01, 2017
US regulators have granted AstraZeneca’s Imfinzi breakthrough status for the treatment of certain patients with locally-advanced, unresectable non-small cell lung cancer
AZ’s Imfinzi scores FDA breakthrough therapy designation in wake of major trial failure pharmafile
August 01, 2017
Still reeling from the public reaction to the flop of its key Mystic trial, where its injectable immunotherapy drug Imfinzi (durvalumab) failed to show any clinically relevant efficacy in stopping lung cancer progression,
AZ, Merck link to develop and commercialise cancer drugs pharmatimes
July 28, 2017
AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
AZ's 'blockbuster' lung cancer drug fails, Q2 revenue falls pharmafile
July 28, 2017
Imfinzi and immune checkpoint blocker tremelimumab were no better at stopping lung cancer progression than standard chemotherapy in patients expressing protein PD-L1 in over 25% of their cancer cells.
AZ unveils new data on Farxiga backing earlier use pharmatimes
June 15, 2017
AstraZeneca has presented findings from a real-world analysis potentially supporting earlier and wider use of the SGLT-2 inhibitor class of drugs in the diabetes treatment pathway.
AZ launches lawsuit against former executive for defecting to GSK pharmafile
May 18, 2017
AstraZeneca has launched a lawsuit against one of its former executives after he jumped ship to join rival pharma giant GlaxoSmithKline.

Previous page 1 2 3 4 5 Next page